Abstract
Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2600-2601 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 106 |
| Issue number | 8 |
| DOIs | |
| State | Published - Oct 2005 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology